

Regulatory and Medical Writing – Supplemental Information

On April 22nd, 2026, Certara announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to \$135 million. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions.

Historical Regulatory and Medical Writing Revenue

1Q24	2Q24	3Q24	4Q24	FY24	1Q25	2Q25	3Q25	4Q25	FY25
\$13.2M	\$13.3M	\$14.1M	\$14.1M	\$54.7M	\$13.5M	\$11.9M	\$13.3M	\$11.7M	\$50.4M

In 2025, the Regulatory and Medical Writing business generated \$50 million in revenue and \$17 million in adjusted EBITDA, excluding unallocated overhead expense.